ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2022. The put-call ratio across all filers is 2.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $27 | +285.7% | 748 | +392.1% | 0.02% | +300.0% |
Q2 2023 | $7 | +40.0% | 152 | +16.9% | 0.01% | +25.0% |
Q1 2023 | $5 | -58.3% | 130 | -49.6% | 0.00% | -20.0% |
Q4 2022 | $12 | -99.8% | 258 | +52.7% | 0.01% | -16.7% |
Q3 2022 | $7,000 | 0.0% | 169 | +36.3% | 0.01% | 0.0% |
Q2 2022 | $7,000 | -22.2% | 124 | -0.8% | 0.01% | 0.0% |
Q1 2022 | $9,000 | +50.0% | 125 | +76.1% | 0.01% | -25.0% |
Q4 2021 | $6,000 | – | 71 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |